Nanotechnology-Enabled Targeted Viricides
	Publicly Traded Company, “NNVC”
	www.nanoviricides.com

 April 20, 2017

Via Edgar Only

United States Securities and Exchange Commission

Mail Stop 6010

Washington, D.C. 20549

Re:	NanoViricides, Inc.
	Registration Statement on Form S-3
	Filed on March 1, 2017
	File No. 333-216345

To Whom It May Concern:

Please be advised that the undersigned is the duly elected Chief Executive Officer of NanoViricides, Inc. (the "Registrant").

Having been advised that the Commission has no comments to the Registrant's Registration Statement on Form S-3 (File No. 333-216345) filed on March 1, 2017, and subsequently amended, the Registrant hereby requests acceleration of the effective date of the Registration Statement to Tuesday, April 25, 2017 at 10:00 a.m., or as soon thereafter as practicable.

The Registrant hereby acknowledges that:

· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Should you have any questions in regard to this correspondence or any other matter relating to this Registrant’s filing, please do not hesitate to contact me.

Very truly yours,

/s/ Eugene Seymour, MD, MPH

Eugene Seymour, MD, MPH

1 Controls Drive, Shelton, CT 06484. Tel./Fax: 203-937-6137.